The Role of Notch in Breast Cancer

  • Jeffrey C. Bloodworth
  • Clodia OsipoEmail author


Women have a one in eight lifetime risk of being diagnosed with breast cancer. Breast cancer is the second leading cause of cancer-related mortality in women worldwide. Notch signaling is critical for proper mammary development and homeostasis. Notch is emerging as an important targetable oncogene in breast cancer. Notch signaling promotes a number of cancer phenotypes including stem cell survival, self-renewal, and differentiation. This chapter will describe research advancements and clinical implications of Notch signaling in the context of the normal mammary gland and in breast cancer. Notch is involved in cross talk with several other signaling pathways. Estrogen receptor alpha and ErbB2 are commonly overexpressed breast oncogenes. Therapies designed to target these receptors are indicated for the majority of invasive breast cancer cases. However, breast tumors are often able to overcome these therapies, and upregulation of Notch is implicated in the development of drug resistance.


Breast cancer Notch Gamma secretase Mammary Breast cancer stem cell 


  1. 1.
    Buono, K. D., et al. (2006). The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Developmental Biology, 293(2), 565–580.PubMedCrossRefGoogle Scholar
  2. 2.
    Van Keymeulen, A., et al. (2011). Distinct stem cells contribute to mammary gland development and maintenance. Nature, 479(7372), 189–193.PubMedCrossRefGoogle Scholar
  3. 3.
    Kleinberg, D. L., & Ruan, W. (2008). IGF-I, GH, and sex steroid effects in normal mammary gland development. Journal of Mammary Gland Biology and Neoplasia, 13(4), 353–360.PubMedCrossRefGoogle Scholar
  4. 4.
    Quarrie, L. H., Addey, C. V., & Wilde, C. J. (1996). Programmed cell death during mammary tissue involution induced by weaning, litter removal, and milk stasis. Journal of Cellular Physiology, 168(3), 559–569.PubMedCrossRefGoogle Scholar
  5. 5.
    Meurette, O., et al. (2009). Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Research, 69(12), 5015–5022.PubMedCrossRefGoogle Scholar
  6. 6.
    Shao, S., et al. (2015). Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner. Molecular Cancer, 14, 28.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Angerer, L. M., & Angerer, R. C. (1999). Regulative development of the sea urchin embryo: Signalling cascades and morphogen gradients. Seminars in Cell & Developmental Biology, 10(3), 327–334.CrossRefGoogle Scholar
  8. 8.
    Kurata, S., et al. (2000). Notch signaling and the determination of appendage identity. Proceedings of the National Academy of Sciences of the United States of America, 97(5), 2117–2122.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Zhu, X., et al. (2006). Sustained Notch signaling in progenitors is required for sequential emergence of distinct cell lineages during organogenesis. Genes & Development, 20(19), 2739–2753.CrossRefGoogle Scholar
  10. 10.
    Dufraine, J., Funahashi, Y., & Kitajewski, J. (2008). Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene, 27(38), 5132–5137.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Chigurupati, S., et al. (2007). Involvement of notch signaling in wound healing. PLoS One, 2(11), e1167.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Petrovic, J., et al. (2014). Ligand-dependent Notch signaling strength orchestrates lateral induction and lateral inhibition in the developing inner ear. Development, 141(11), 2313–2324.PubMedCrossRefGoogle Scholar
  13. 13.
    Barad, O., Hornstein, E., & Barkai, N. (2011). Robust selection of sensory organ precursors by the Notch-Delta pathway. Current Opinion in Cell Biology, 23(6), 663–667.PubMedCrossRefGoogle Scholar
  14. 14.
    Logeat, F., et al. (1998). The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proceedings of the National Academy of Sciences of the United States of America, 95(14), 8108–8112.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Rand, M. D., et al. (2000). Calcium depletion dissociates and activates heterodimeric notch receptors. Molecular and Cellular Biology, 20(5), 1825–1835.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    D'Souza, B., Meloty-Kapella, L., & Weinmaster, G. (2010). Canonical and non-canonical Notch ligands. Current Topics in Developmental Biology, 92, 73–129.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Hartmann, D., et al. (2002). The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Human Molecular Genetics, 11(21), 2615–2624.PubMedCrossRefGoogle Scholar
  18. 18.
    Sastre, M., et al. (2001). Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Reports, 2(9), 835–841.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Dontu, G., et al. (2004). Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Research, 6(6), R605–R615.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Lafkas, D., et al. (2013). Notch3 marks clonogenic mammary luminal progenitor cells in vivo. The Journal of Cell Biology, 203(1), 47–56.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Bouras, T., et al. (2008). Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell, 3(4), 429–441.PubMedCrossRefGoogle Scholar
  22. 22.
    Cantrell, M. A., et al. (2015). C-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression. Oncotarget, 6(14), 11863–11881.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Domingo, L., et al. (2014). Tumor phenotype and breast density in distinct categories of interval cancer: Results of population-based mammography screening in Spain. Breast Cancer Research, 16(1), R3.PubMedCrossRefGoogle Scholar
  24. 24.
    Schnitt, S. J. (2010). Classification and prognosis of invasive breast cancer: From morphology to molecular taxonomy. Modern Pathology, 23(Suppl 2), S60–S64.PubMedCrossRefGoogle Scholar
  25. 25.
    Prat, A., et al. (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research, 12(5), R68.PubMedCrossRefGoogle Scholar
  26. 26.
    Yerushalmi, R., et al. (2010). Ki67 in breast cancer: Prognostic and predictive potential. The Lancet Oncology, 11(2), 174–183.PubMedCrossRefGoogle Scholar
  27. 27.
    Bastien, R. R., et al. (2012). PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Medical Genomics, 5, 44.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Gallahan, D., & Callahan, R. (1997). The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). Oncogene, 14(16), 1883–1890.PubMedCrossRefGoogle Scholar
  29. 29.
    Gallahan, D., Kozak, C., & Callahan, R. (1987). A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17. Journal of Virology, 61(1), 218–220.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Reedijk, M., et al. (2005). High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Research, 65(18), 8530–8537.PubMedCrossRefGoogle Scholar
  31. 31.
    Yuan, X., et al. (2015). Expression of Notch1 correlates with breast cancer progression and prognosis. PLoS One, 10(6), e0131689.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Reedijk, M., et al. (2008). JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Research and Treatment, 111(3), 439–448.PubMedCrossRefGoogle Scholar
  33. 33.
    Chu, D., et al. (2011). Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. Annals of Oncology, 22(11), 2440–2447.PubMedCrossRefGoogle Scholar
  34. 34.
    Li, L., et al. (2014). Notch-1 signaling promotes the malignant features of human breast cancer through NF-kappaB activation. PLoS One, 9(4), e95912.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Tremblay, I., et al. (2013). The MEK/ERK pathway promotes NOTCH signalling in pancreatic cancer cells. PLoS One, 8(12), e85502.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Klinakis, A., et al. (2006). Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proceedings of the National Academy of Sciences of the United States of America, 103(24), 9262–9267.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Cohen, B., et al. (2010). Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Research and Treatment, 123(1), 113–124.PubMedCrossRefGoogle Scholar
  38. 38.
    Vermezovic, J., et al. (2015). Notch is a direct negative regulator of the DNA-damage response. Nature Structural & Molecular Biology, 22(5), 417–424.CrossRefGoogle Scholar
  39. 39.
    Stylianou, S., Clarke, R. B., & Brennan, K. (2006). Aberrant activation of notch signaling in human breast cancer. Cancer Research, 66(3), 1517–1525.PubMedCrossRefGoogle Scholar
  40. 40.
    Yun, J., et al. (2015). p53 modulates Notch signaling in MCF-7 breast cancer cells by associating with the Notch transcriptional complex via MAML1. Journal of Cellular Physiology, 230(12), 3115–3127.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Early Breast Cancer Trialists’ Collaborative, G, et al. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771–784.CrossRefGoogle Scholar
  42. 42.
    Deome, K. B., et al. (1959). Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Research, 19(5), 515–520.PubMedGoogle Scholar
  43. 43.
    Ricardo, S., et al. (2011). Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution within intrinsic molecular subtype. Journal of Clinical Pathology, 64(11), 937–946.PubMedCrossRefGoogle Scholar
  44. 44.
    Neumeister, V., et al. (2010). In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. The American Journal of Pathology, 176(5), 2131–2138.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Harrison, H., et al. (2010). Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Research, 70(2), 709–718.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Grudzien, P., et al. (2010). Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Research, 30(10), 3853–3867.PubMedGoogle Scholar
  47. 47.
    Park, Y. H., et al. (2011). Clinical relevance of TNM staging system according to breast cancer subtypes. Annals of Oncology, 22(7), 1554–1560.PubMedCrossRefGoogle Scholar
  48. 48.
    Sethi, N., et al. (2011). Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell, 19(2), 192–205.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    McGowan, P. M., et al. (2011). Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Molecular Cancer Research, 9(7), 834–844.PubMedCrossRefGoogle Scholar
  50. 50.
    Martin, T. A., et al. (2005). Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Annals of Surgical Oncology, 12(6), 488–496.PubMedCrossRefGoogle Scholar
  51. 51.
    Leong, K. G., et al. (2007). Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through slug-induced repression of E-cadherin. The Journal of Experimental Medicine, 204(12), 2935–2948.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Faronato, M., et al. (2015). DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation. Oncotarget, 6(26), 22467–22479.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Farnie, G., et al. (2007). Novel cell culture technique for primary ductal carcinoma in situ: Role of Notch and epidermal growth factor receptor signaling pathways. Journal of the National Cancer Institute, 99(8), 616–627.PubMedCrossRefGoogle Scholar
  54. 54.
    Farnie, G., et al. (2013). Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status. PLoS One, 8(2), e56840.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Tanos, T., et al. (2012). ER and PR signaling nodes during mammary gland development. Breast Cancer Research, 14(4), 210.PubMedCrossRefGoogle Scholar
  56. 56.
    Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2000). Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Research, 2(5), 335–344.PubMedCrossRefGoogle Scholar
  57. 57.
    Wardell, S. E., Marks, J. R., & McDonnell, D. P. (2011). The turnover of estrogen receptor alpha by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochemical Pharmacology, 82(2), 122–130.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Goss, P. E., & Strasser, K. (2001). Aromatase inhibitors in the treatment and prevention of breast cancer. Journal of Clinical Oncology, 19(3), 881–894.PubMedCrossRefGoogle Scholar
  59. 59.
    Rizzo, P., et al. (2008). Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Research, 68(13), 5226–5235.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Hao, L., et al. (2010). Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene, 29(2), 201–213.PubMedCrossRefGoogle Scholar
  61. 61.
    Simoes, B. M., et al. (2015). Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity. Cell Reports, 12(12), 1968–1977.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Lombardo, Y., et al. (2014). Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Research, 16(3), R62.PubMedCrossRefGoogle Scholar
  63. 63.
    Arteaga, C. L., et al. (2012). Treatment of HER2-positive breast cancer: Current status and future perspectives. Nature Reviews. Clinical Oncology, 9(1), 16–32.CrossRefGoogle Scholar
  64. 64.
    Han, M., Deng, H. Y., & Jiang, R. (2012). Effect of trastuzumab on Notch-1 signaling pathway in breast cancer SK-BR3 cells. Chinese Journal of Cancer Research, 24(3), 213–219.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Osipo, C., et al. (2008). ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene, 27(37), 5019–5032.PubMedCrossRefGoogle Scholar
  66. 66.
    Abravanel, D. L., et al. (2015). Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. Journal of Clinical Investigation, 125(6), 2484–2496.PubMedCrossRefGoogle Scholar
  67. 67.
    Pandya, K., et al. (2016). PKCalpha attenuates Jagged-1-mediated Notch signaling in ErbB-2-positive breast cancer to reverse trastuzumab resistance. Clinical Cancer Research, 22(1), 175–186.PubMedCrossRefGoogle Scholar
  68. 68.
    Manni, A., et al. (1996). Induction of a less aggressive breast cancer phenotype by protein kinase C-alpha and -beta overexpression. Cell Growth & Differentiation, 7(9), 1187–1198.Google Scholar
  69. 69.
    Severson, T. M., et al. (2015). BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Molecular Oncology, 9(8), 1528–1538.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Tommiska, J., et al. (2008). The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene, 27(17), 2501–2506.PubMedCrossRefGoogle Scholar
  71. 71.
    Ross, J. S., et al. (2015). Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Research and Treatment, 154(1), 155–162.PubMedCrossRefGoogle Scholar
  72. 72.
    Wang, K., et al. (2015). PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor. Clinical Cancer Research, 21(6), 1487–1496.PubMedCrossRefGoogle Scholar
  73. 73.
    Phuah, S. Y., et al. (2012). Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer. Breast Cancer Research, 14(6), R142.PubMedCrossRefGoogle Scholar
  74. 74.
    Speiser, J., et al. (2012). Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. International Journal of Surgical Pathology, 20(2), 139–145.PubMedCrossRefGoogle Scholar
  75. 75.
    Lee, C. W., et al. (2008). A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Research, 10(6), R97.PubMedCrossRefGoogle Scholar
  76. 76.
    Clementz, A. G., et al. (2011). NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: Novel therapeutic implications. Breast Cancer Research, 13(3), R63.PubMedCrossRefGoogle Scholar
  77. 77.
    Yamamoto, M., et al. (2013). NF-kappaB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nature Communications, 4, 2299.PubMedCrossRefGoogle Scholar
  78. 78.
    Bhola, N. E., et al. (2016). Treatment of triple negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and Notch-dependent cancer stem cell population. Cancer Research, 76(2), 440–452.PubMedCrossRefGoogle Scholar
  79. 79.
    Chinchar, E., et al. (2014). Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vascular Cell, 6, 12.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Microbiology and Immunology, Oncology Research Institute, Biochemistry and Molecular Biology ProgramLoyola University ChicagoMaywoodUSA

Personalised recommendations